From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

Psychiatric Comorbidities of Myeloma Lead to High Health-Care Costs

Many patients with multiple myeloma (MM) have a high risk for developing psychiatric comorbidities and, according to a study published in Blood Advances, managing...
WIB_icon

Treating MPNs With JAK1/2 Inhibitors Increases Risks for B-Cell Lymphomas

JAK1/2 inhibitors have been used as standard and experimental treatment of myeloproliferative neoplasms (MPNs) for years, but according to research published in Blood, their...

Lower Risk of GVHD With Parous Female Sibling Donors Than With Male Unrelated Donors

Donor’s sex and number of previous pregnancies are well established risk factors for graft-versus-host disease (GVHD) in hematopoietic cell transplantation (HCT), with male sibling...

Could Cord Blood Transplantation Cure Refractory Severe Aplastic Anemia?

In children and young adults with refractory severe aplastic anemia (SAA) without matched, unrelated donors, cord blood transplantation was associated with low rates of...

Are Strict Eligibility Criteria Keeping Patients From Clinical Trial Participation?

Eligibility criteria for clinical trials of leukemia therapies may be overly restrictive, limiting trial results’ applicability to real-world clinical practice and leading to unbalanced...
WIB_icon

Study Finds Thromboembolism Is a Frequent Complication of ALL Treatment

Adolescents and adults with acute lymphocytic leukemia (ALL) are at a “markedly” increased risk for developing thromboembolism (TE), even when treated according to the...
WIB_icon

Children With Ambiguous Leukemia Fare Better With Lymphoid-Directed Treatment

While most patients with acute leukemia have disease with a lymphoid or myeloid linage, 2 to 5 percent have “acute leukemia of ambiguous lineage”...

Can Pevonedistat Improve Azacitidine’s Activity in Older Patients With AML?

Adding pevonedistat, a first-in-class inhibitor of the NEDD8-activating enzyme (NAE), to azacitidine led to responses in patients with acute myeloid leukemia (AML), according to...
WIB_icon

Long-Term PACE Follow-Up Confirms Ponatinib’s Benefit in CP-CML

At five-year follow-up, treatment with the third-generation tyrosine kinase inhibitor (TKI) ponatinib led to deep and durable responses in patients with heavily pretreated chronic-phase...

Standardized MRD Assay for FLT3-ITD-Mutated AML Could Guide AML Therapy Decisions

In a report published in Blood Advances, researchers describe a standardized minimal residual disease (MRD) assay that can detect FLT3-ITD mutations in patients with...
Advertisement

Current Issue

July 2018 Bonus Mid-Year Edition

This bonus issue features a look at the most recent changes to Maintenance of Certification programs, highlights from recent hematology/oncology meetings, and more.